Literature DB >> 1554036

Haloperidol plasma levels and clinical response: a therapeutic window relationship.

T Van Putten1, S R Marder, J Mintz, R E Poland.   

Abstract

OBJECTIVE: The purpose of the study was to assess the relationship between plasma haloperidol and clinical response.
METHOD: Sixty-nine newly admitted drug-free schizophrenic men were randomly assigned to receive haloperidol, 5, 10, or 20 mg daily for 4 weeks, and clinical response was measured at the end of the fixed-dose period. Haloperidol was assayed by a sensitive and specific radioimmunoassay.
RESULTS: The authors found a curvilinear relationship between clinical response and plasma haloperidol during fixed-dose treatment, with an apparent optimum between 5 and 12 ng/ml. When plasma levels above 12 ng/ml were lowered to the 5-12 ng/ml range, all patients improved to varying degrees and no patient deteriorated. When plasma levels of nonresponders within this therapeutic window were raised above 12 ng/ml (as in routine practice), they, on balance, deteriorated in that they became more dysphoric. With the 20-mg dose, half the patients had plasma levels above 12 ng/ml.
CONCLUSIONS: In this sample of newly admitted schizophrenic men, optimal clinical response occurred with a plasma haloperidol range of 5-12 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1554036     DOI: 10.1176/ajp.149.4.500

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  15 in total

Review 1.  Therapeutic drug monitoring and patient outcome. A review of the issues.

Authors:  A L Tonkin; F Bochner
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

2.  A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs.

Authors:  R A Roemer; E Richelson; C Shagass; L Leventhal
Journal:  J Psychiatry Neurosci       Date:  1996-11       Impact factor: 6.186

Review 3.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 4.  Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.

Authors:  W W Fleischhacker; M Hummer
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

5.  Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application.

Authors:  W Seiler; H Wetzel; A Hillert; G Schöllnhammer; M Langer; U Barlage; C Hiemke
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

6.  Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder.

Authors:  M Hornig; T Briese; J Licinio; R F Khabbaz; L L Altshuler; S G Potkin; M Schwemmle; U Siemetzki; J Mintz; K Honkavuori; H C Kraemer; M F Egan; P C Whybrow; W E Bunney; W I Lipkin
Journal:  Mol Psychiatry       Date:  2012-01-31       Impact factor: 15.992

Review 7.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

Review 8.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

Review 9.  Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Authors:  K K Midha; J W Hubbard; S R Marder; B D Marshall; T Van Putten
Journal:  J Psychiatry Neurosci       Date:  1994-07       Impact factor: 6.186

Review 10.  Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.

Authors:  Delia Bishara; David Taylor
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.